Form 8-K - Current report:
SEC Accession No. 0000950170-25-058966
Filing Date
2025-04-28
Accepted
2025-04-28 08:01:17
Documents
15
Period of Report
2025-04-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apvo-20250428.htm   iXBRL 8-K 56306
2 EX-1.1 apvo-ex1_1.htm EX-1.1 370881
3 EX-5.1 apvo-ex5_1.htm EX-5.1 31181
4 GRAPHIC img57496738_0.jpg GRAPHIC 18656
5 GRAPHIC img57496738_1.jpg GRAPHIC 18656
  Complete submission text file 0000950170-25-058966.txt   687801

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT apvo-20250428.xsd EX-101.SCH 24892
17 EXTRACTED XBRL INSTANCE DOCUMENT apvo-20250428_htm.xml XML 4697
Mailing Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121
Business Address 2401 4TH AVE. SUITE 1050 SEATTLE WA 98121 206-838-0500
Aptevo Therapeutics Inc. (Filer) CIK: 0001671584 (see all company filings)

EIN.: 811567056 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37746 | Film No.: 25875997
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)